$ATAI
ATAI Life Sciences NV

2022 Q1 Form 10-Q Financial Statement

#000095017022009966 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $19.88M
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.98M $9.273M
YoY Change 93.92% 490.64%
% of Gross Profit
Research & Development $15.46M $5.585M
YoY Change 176.81% 160.98%
% of Gross Profit
Depreciation & Amortization $60.00K $6.000K
YoY Change 900.0%
% of Gross Profit
Operating Expenses $33.44M $15.83M
YoY Change 111.26% 326.68%
Operating Profit -$33.44M $4.050M
YoY Change -925.73%
Interest Expense $2.261M $178.0K
YoY Change 1170.22% -99.1%
% of Operating Profit 4.4%
Other Income/Expense, Net $1.521M $1.703M
YoY Change -10.69% -2.13%
Pretax Income -$31.92M $5.753M
YoY Change -654.86% -67.86%
Income Tax $41.00K $6.000K
% Of Pretax Income 0.1%
Net Earnings -$36.87M $688.0K
YoY Change -5458.87% -95.78%
Net Earnings / Revenue 3.46%
Basic Earnings Per Share -$0.24 $0.01
Diluted Earnings Per Share -$0.24 $0.01
COMMON SHARES
Basic Shares Outstanding 160.7M
Diluted Shares Outstanding 153.5M 121.4M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $334.9M
YoY Change
Cash & Equivalents $124.0M $104.4M
Short-Term Investments $210.9M
Other Short-Term Assets $1.389M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $348.8M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $178.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $9.749M
YoY Change
Other Assets $7.504M
YoY Change
Total Long-Term Assets $34.95M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $348.8M
Total Long-Term Assets $34.95M
Total Assets $383.7M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.612M
YoY Change
Accrued Expenses $18.25M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $210.9M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.09M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $725.0K
YoY Change
Other Long-Term Liabilities $4.126M
YoY Change
Total Long-Term Liabilities $4.126M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $22.09M
Total Long-Term Liabilities $4.126M
Total Liabilities $29.38M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$394.7M
YoY Change
Common Stock $18.01M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $346.0M
YoY Change
Total Liabilities & Shareholders Equity $383.7M
YoY Change

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$36.87M $688.0K
YoY Change -5458.87% -95.78%
Depreciation, Depletion And Amortization $60.00K $6.000K
YoY Change 900.0%
Cash From Operating Activities -$23.99M -$16.52M
YoY Change 45.16%
INVESTING ACTIVITIES
Capital Expenditures $56.00K $175.0K
YoY Change -68.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $191.0K
YoY Change -100.0%
Cash From Investing Activities -$214.7M -$3.721M
YoY Change 5670.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.000M $28.37M
YoY Change -96.48%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 132.0K 30.50M
YoY Change -99.57%
NET CHANGE
Cash From Operating Activities -23.99M -16.52M
Cash From Investing Activities -214.7M -3.721M
Cash From Financing Activities 132.0K 30.50M
Net Change In Cash -238.3M 7.123M
YoY Change -3445.37%
FREE CASH FLOW
Cash From Operating Activities -$23.99M -$16.52M
Capital Expenditures $56.00K $175.0K
Free Cash Flow -$24.04M -$16.70M
YoY Change 43.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001840904
CY2021Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
1350
CY2021Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
1654
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
00000
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40493
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
ATAI Life Sciences N.V.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
ATAI Life Sciences N.V. c/o Mindspace
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Krausenstraße 9-10
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Berlin
CY2022Q1 dei Entity Address Country
EntityAddressCountry
DE
CY2022Q1 dei City Area Code
CityAreaCode
49 89
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
2153 9035
CY2022Q1 dei Security12b Title
Security12bTitle
Common shares, par value €0.10 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
ATAI
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7341000
CY2022Q1 us-gaap Assets
Assets
383732000
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
160732785
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123975000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
362266000
CY2022Q1 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
210939000
CY2021Q4 atai Debt Securities Carried At Fair Value
DebtSecuritiesCarriedAtFairValue
0
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12985000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11903000
CY2022Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
887000
CY2021Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
913000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
348786000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
375082000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
178000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
149000
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
9749000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
16131000
CY2022Q1 us-gaap Other Long Term Investments
OtherLongTermInvestments
10587000
CY2021Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
11628000
CY2022Q1 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
6928000
CY2021Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
3835000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7504000
CY2021Q4 us-gaap Assets
Assets
414166000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3612000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6004000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18252000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14829000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
51000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
227000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
51000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
22091000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20935000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2433000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2432000
CY2022Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
725000
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
743000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4126000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4097000
CY2022Q1 us-gaap Liabilities
Liabilities
29375000
CY2021Q4 us-gaap Liabilities
Liabilities
28207000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
160719828
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
160719828
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
160677001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
160677001
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
18007000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
18002000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
735380000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
725045000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12709000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8336000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394672000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-357803000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
346006000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
376908000
CY2022Q1 us-gaap Minority Interest
MinorityInterest
8351000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
9051000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
354357000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
385959000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
383732000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
414166000
CY2022Q1 us-gaap Revenues
Revenues
0
CY2021Q1 us-gaap Revenues
Revenues
19880000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15460000
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5585000
CY2022Q1 atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
0
CY2021Q1 atai Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
972000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17982000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9273000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
33442000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
15830000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-33442000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4050000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
98000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-251000
CY2022Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
CY2021Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-41000
CY2022Q1 us-gaap Increase Decrease In Debt Securities Trading
IncreaseDecreaseInDebtSecuritiesTrading
-740000
CY2021Q1 us-gaap Increase Decrease In Debt Securities Trading
IncreaseDecreaseInDebtSecuritiesTrading
0
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2163000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1491000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-117000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1521000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1703000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-31921000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5753000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-5596000
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1703000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-37558000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
4044000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-689000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3356000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36869000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
688000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
153529268
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
119258529
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153529268
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121374430
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-37558000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
4044000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4373000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3842000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-41931000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
202000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-689000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
3356000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-11000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-184000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-700000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
3172000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41231000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2970000
CY2021Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
385959000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
132000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10208000
CY2022Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-4384000
CY2022Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-37558000
CY2022Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
354357000
CY2020Q4 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
95368000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4900000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23510000
CY2021Q1 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
885000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
212000
CY2021Q1 atai Foreign Currency Translation Adjustment Net Of Tax
ForeignCurrencyTranslationAdjustmentNetOfTax
-4026000
CY2021Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
4044000
CY2021Q1 atai Stockholder Equity Including Portion Attributable To Noncontrolling Interest
StockholderEquityIncludingPortionAttributableToNoncontrollingInterest
119993000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-37558000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
4044000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
97000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-251000
CY2022Q1 us-gaap Increase Decrease In Debt Securities Trading
IncreaseDecreaseInDebtSecuritiesTrading
-740000
CY2021Q1 us-gaap Increase Decrease In Debt Securities Trading
IncreaseDecreaseInDebtSecuritiesTrading
0
CY2022Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
CY2021Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-41000
CY2022Q1 atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
5596000
CY2021Q1 atai Income Losses From Equity Method Investments
IncomeLossesFromEquityMethodInvestments
1703000
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
972000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10208000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
212000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1519000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-60000
CY2021Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
20000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20000000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1289000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1813000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1886000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3811000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1722000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5404000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
120000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23986000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16524000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
175000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
211680000
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
CY2022Q1 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2021Q1 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
10000
CY2022Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0
CY2021Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
468000
CY2022Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0
CY2021Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
762000
CY2022Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
0
CY2021Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
2035000
CY2022Q1 us-gaap Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
0
CY2021Q1 us-gaap Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
100000
CY2022Q1 us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
3000000
CY2021Q1 us-gaap Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
0
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
CY2021Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
191000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-214736000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3721000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28370000
CY2022Q1 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
0
CY2021Q1 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
801000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
534000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
132000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
CY2021Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
2417000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
777000
CY2022Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2021Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
756000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30499000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
299000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3131000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-238291000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7123000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
362266000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97246000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123975000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104369000
CY2022Q1 atai Common Stock Issuance Costs In Accounts Payable
CommonStockIssuanceCostsInAccountsPayable
0
CY2021Q1 atai Common Stock Issuance Costs In Accounts Payable
CommonStockIssuanceCostsInAccountsPayable
89000
CY2022Q1 atai Common Stock Issuance Costs In Accrued Liabilities
CommonStockIssuanceCostsInAccruedLiabilities
0
CY2021Q1 atai Common Stock Issuance Costs In Accrued Liabilities
CommonStockIssuanceCostsInAccruedLiabilities
4771000
CY2022Q1 atai Deferred Offering Costs In Accounts Payable
DeferredOfferingCostsInAccountsPayable
0
CY2021Q1 atai Deferred Offering Costs In Accounts Payable
DeferredOfferingCostsInAccountsPayable
69000
CY2022Q1 atai Deferred Offering Costs In Accrued Liabilities
DeferredOfferingCostsInAccruedLiabilities
0
CY2021Q1 atai Deferred Offering Costs In Accrued Liabilities
DeferredOfferingCostsInAccruedLiabilities
1774000
CY2022Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0
CY2021Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
885000
CY2022Q1 atai Issuance Of Derivative Instrument Related To Convertible Promissory Notes
IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes
0
CY2021Q1 atai Issuance Of Derivative Instrument Related To Convertible Promissory Notes
IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes
304000
CY2022Q1 atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
245000
CY2021Q1 atai Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
0
CY2022Q1 atai Share Subscriptions Receivable
ShareSubscriptionsReceivable
0
CY2021Q1 atai Share Subscriptions Receivable
ShareSubscriptionsReceivable
140868000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="footnotes" style="text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. Or</span><span id="notes"/><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ganization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ATAI Life Sciences N.V. (“atai”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since inception, atai has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which atai is the primary beneficiary under the VIE model (collectively, the “Company”). atai is headquartered in Berlin, Germany.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has determined that it has one operating and reporting segment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate Reorganization and Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">atai was incorporated pursuant to the laws of the Netherlands as a Dutch private company with limited liability on September 10, 2020 for the purposes of becoming a holding company for ATAI Life Sciences AG and consummating the corporate reorganization described below. atai did not conduct any operations prior to the corporate reorganization other than activities incidental to its formation. ATAI Life Sciences AG was formed as a separate company on February 7, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In contemplation of the consummation of atai’s initial public offering (“IPO”) of common shares, atai undertook a corporate reorganization (the “Corporate Reorganization”). The Corporate Reorganization consisted of several steps as described below:</span></p><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exchange of ATAI Life Sciences AG Securities for ATAI Life Sciences B.V. Common Shares and Share Split</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">: In April 2021, the existing shareholders of ATAI Life Sciences AG each became a party to a separate notarial deed of issue under Dutch law and (i) subscribed for new common shares in ATAI Life Sciences B.V. and (ii) transferred their respective shares in ATAI Life Sciences AG, on a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 to 10 basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (the “Exchange Ratio”), to ATAI Life Sciences B.V. as a contribution in kind on the common shares in ATAI Life Sciences B.V. As a result of the issuance of common shares in ATAI Life Sciences B.V. to the shareholders of ATAI Life Sciences AG and the contribution and transfer of their respective shares in ATAI Life Sciences AG to ATAI Life Sciences B.V., ATAI Life Sciences AG became a wholly owned subsidiary of ATAI Life Sciences B.V. No shareholder rights or preferences changed as a result of the share for share exchange. In connection with such exchange, the common share in ATAI Life Sciences B.V. held by Apeiron was cancelled. On June 7, 2021, shares of ATAI Life Sciences B.V. were split applying a ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.6 to one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and the nominal value of the shares was reduced to €</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, pursuant to a shareholders’ resolution and amendment to the articles of association.</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Conversion of ATAI Life Sciences B.V. into ATAI Life Sciences N.V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.: Immediately preceding the Company’s IPO, the legal form of ATAI Life Sciences B.V. was converted from a Dutch private company with limited liability to a Dutch public company, and the articles of association of ATAI Life Sciences N.V., became effective. Following the Corporate Reorganization, ATAI Life Sciences N.V. became the holding company of ATAI Life Sciences AG.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Corporate Reorganization, as described above, is considered a continuation of ATAI Life Sciences AG resulting in no change in the carrying values of assets or liabilities. As a result, the financial statements for periods prior to the Corporate Reorganization are the financial statements of ATAI Life Sciences AG as the predecessor to atai for accounting and reporting purposes. All share, per-share and related information presented in these condensed consolidated financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share exchange and share split resulting from the Corporate Reorganization. In connection with the Corporate Reorganization, outstanding share awards and option grants of ATAI Life Sciences AG were exchanged for share awards and option grants of ATAI Life Sciences B.V. with identical restrictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On June 22, 2021, atai closed the IPO of its common shares on the Nasdaq Stock Market ("Nasdaq"). As part of the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">17,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common shares, which included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">231.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million from the IPO, after deducting underwriters’ discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impact of COVID-19 Pandemic</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic has continued to present global public health and economic challenges during the three months ended March 31, 2022. Although some research and development timelines have been impacted by delays related to the COVID-19 pandemic, the Company has not experienced material financial impacts on its business and operations as a result. The Company continues to monitor the impact of the COVID-19 pandemic on its employees and business and has undertaken business continuity measures to mitigate potential disruption to its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The future impact of COVID-19 on the Company’s business and operations, including its research and development programs and related clinical trials, will largely depend on future developments, which are highly uncertain, such as the duration of the pandemic, the spread of the disease and variants thereof, the availability and effectiveness of vaccines and related roll-out efforts, breakthrough infections among the vaccinated, vaccine hesitancy, the implementation of vaccine mandates, travel restrictions, social distancing and related government actions around the world, business closures or business disruptions and the ultimate impact of COVID-19 on financial markets and the global economy. For a discussion of the risks to the Company's business from COVID-19, refer to the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">124.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, short-term debt securities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">210.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">394.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has historically financed its operations through the sale of equity securities, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents and short-term debt securities as of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the condensed consolidated financial statements are issued.</span></p>
CY2022Q1 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
1 to 10 basis
CY2021Q2 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
1.6 to one
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124000000.0
CY2022Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
210900000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394700000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s investment in Intelgenx Technologies Corp. (“IntelGenx”), warrant liability with Neuronasal Inc., contingent consideration liability—related parties, derivative liability associated with the Perception convertible promissory notes, in-process research and development assets (“IPRD”), redeemable noncontrolling interests and noncontrolling interests recognized in acquisitions, the valuations of common shares prior to IPO and share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1000000.0
CY2021Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.80
CY2022Q1 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.80
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
248316000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
100000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
CY2021Q1 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
100000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
9051000
CY2022Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
-689000
CY2022Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-11000
CY2022Q1 us-gaap Minority Interest
MinorityInterest
8351000
CY2020Q4 us-gaap Minority Interest
MinorityInterest
4546000
CY2021Q1 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
885000
CY2021Q1 atai Net Income Loss Attributable To Noncontrolling Interest Common
NetIncomeLossAttributableToNoncontrollingInterestCommon
870000
CY2021Q1 atai Net Income Loss Attributable To Noncontrolling Interest Preferred
NetIncomeLossAttributableToNoncontrollingInterestPreferred
2486000
CY2021Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest
-184000
CY2021Q1 us-gaap Minority Interest
MinorityInterest
8603000
CY2022Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
0
CY2021Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
0
CY2022Q1 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
10600000
CY2022Q1 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
6900000
CY2021Q4 us-gaap Variable Interest Entity Entity Maximum Loss Exposure Amount
VariableInterestEntityEntityMaximumLossExposureAmount
11600000
CY2021Q4 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
3800000
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
9749000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
16131000
CY2022Q1 us-gaap Other Long Term Investments
OtherLongTermInvestments
10587000
CY2021Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
11628000
CY2022Q1 atai Equity Method Investment Shares Transaction Date
EquityMethodInvestmentSharesTransactionDate
2026-12-31
CY2022Q1 us-gaap Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions
SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions
9600000
CY2022Q1 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2400000
CY2022Q1 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0
CY2021Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3000000.0
CY2022Q1 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
100000
CY2021Q4 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
100000
CY2021Q4 atai Fair Value Of Common Stock By Applying Discount For Lack Of Marketability
FairValueOfCommonStockByApplyingDiscountForLackOfMarketability
0.050
CY2022Q1 atai Fair Value Of Common Stock By Applying Discount For Lack Of Marketability
FairValueOfCommonStockByApplyingDiscountForLackOfMarketability
0.050
CY2022Q1 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
3960000
CY2021Q4 atai Prepaid Research And Development Related Expenses
PrepaidResearchAndDevelopmentRelatedExpenses
2692000
CY2022Q1 atai Research And Development Tax Credit Current
ResearchAndDevelopmentTaxCreditCurrent
233000
CY2021Q4 atai Research And Development Tax Credit Current
ResearchAndDevelopmentTaxCreditCurrent
742000
CY2022Q1 us-gaap Prepaid Taxes
PrepaidTaxes
5977000
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
4664000
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1426000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3049000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1389000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
756000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12985000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11903000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4240000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2667000
CY2022Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
7781000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
8137000
CY2022Q1 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4703000
CY2021Q4 atai Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
861000
CY2022Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1108000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2832000
CY2022Q1 atai Accrued Advisory Fees Current
AccruedAdvisoryFeesCurrent
78000
CY2021Q4 atai Accrued Advisory Fees Current
AccruedAdvisoryFeesCurrent
169000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
342000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
163000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18252000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14829000
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
152200000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4900000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
0
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-5000
CY2022Q1 us-gaap Convertible Debt
ConvertibleDebt
725000
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
743000
CY2021Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1300000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21411208
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
400000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-37558000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
4044000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-689000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3356000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36869000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
688000
CY2022Q1 atai Effect Of Conversion Of The2018 Convertible Promissory Notes Related Parties
EffectOfConversionOfThe2018ConvertiblePromissoryNotesRelatedParties
0
CY2021Q1 atai Effect Of Conversion Of The2018 Convertible Promissory Notes Related Parties
EffectOfConversionOfThe2018ConvertiblePromissoryNotesRelatedParties
-75000
CY2022Q1 atai Net Income Loss Attributable To Atai Life Sciences Nv Shareholders Diluted
NetIncomeLossAttributableToAtaiLifeSciencesNVShareholdersDiluted
-36869000
CY2021Q1 atai Net Income Loss Attributable To Atai Life Sciences Nv Shareholders Diluted
NetIncomeLossAttributableToAtaiLifeSciencesNVShareholdersDiluted
613000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
153529268
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
119258529
CY2022Q1 atai Effect Of Dilutive Stock Options To Purchase Common Stock
EffectOfDilutiveStockOptionsToPurchaseCommonStock
0
CY2021Q1 atai Effect Of Dilutive Stock Options To Purchase Common Stock
EffectOfDilutiveStockOptionsToPurchaseCommonStock
2115901
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153529268
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121374430
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50168788
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23567072

Files In Submission

Name View Source Status
0000950170-22-009966-index-headers.html Edgar Link pending
0000950170-22-009966-index.html Edgar Link pending
0000950170-22-009966.txt Edgar Link pending
0000950170-22-009966-xbrl.zip Edgar Link pending
atai-20220331.htm Edgar Link pending
atai-20220331.xsd Edgar Link pending
atai-20220331_cal.xml Edgar Link unprocessable
atai-20220331_def.xml Edgar Link unprocessable
atai-20220331_htm.xml Edgar Link completed
atai-20220331_lab.xml Edgar Link unprocessable
atai-20220331_pre.xml Edgar Link unprocessable
atai-ex31_1.htm Edgar Link pending
atai-ex31_2.htm Edgar Link pending
atai-ex32_1.htm Edgar Link pending
atai-ex32_2.htm Edgar Link pending
atai-ex4_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img105015185_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending